Navigation Links
BIO Ventures for Global Health Announces Management Changes
Date:6/25/2009

Christopher D. Earl Resigning as CEO

Board member Melinda Moree named interim leader

WASHINGTON, June 25 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced that Christopher D. Earl, Ph.D., will resign from BVGH, effective July 9, 2009. Melinda Moree, Ph.D., a member of the board since BVGH's inception, will serve as interim CEO until a permanent replacement is hired.

"I've been galvanized by my experience in global health and honored to have the opportunity to contribute," says Dr. Earl. "I look forward to continuing to work at the interface of public health, science, and entrepreneurship."

"Chris's imagination and expertise have enabled BVGH to demonstrate the integral role the biotechnology industry can play in addressing the urgent medical needs of developing countries," says Robert B. Chess, Chairman of BVGH. "From promoting new financial incentives that reward companies for investing in global health R&D, to creating Innovation Maps that define a path toward making new breakthrough therapies, we thank Chris for his commitment and contributions. In particular, we are pleased that BVGH secured a three-year, $7 million renewal of funding from the Bill & Melinda Gates Foundation under Chris' leadership."

Melinda Moree, Ph.D., previously served as Executive Director for the PATH Malaria Vaccine Initiative, a $50 million/year Product Development Partnership funded by the Bill & Melinda Gates Foundation. She also served as Vice President, Global Health Services, Applied Strategies, supporting global, regional, and national health organizations in their mission to improve human health worldwide.

"BVGH has had an impact through initiatives launched by Chris such as last year's Partnering for Global Health Forum that brought together biotechnology executives and global health innovators," says Jim Greenwood, President and CEO of the Biotechnology Industry Organization and a member of the BVGH Board. "We look forward to continued success through Melinda's knowledge of BVGH and depth of experience in forging partnerships between the private and public sectors to keep BVGH operating at a high level."

About BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for infectious diseases of the developing world. BVGH breaks down barriers that hinder industry initiatives in global health product development. We foster collaboration among stakeholders in industry, philanthropy, academia, and government, and we catalyze industry investment through the creation of new market-based incentives. For more information please visit www.bvgh.org.


'/>"/>
SOURCE BIO Ventures for Global Health
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 NX Prenatal Inc., a US ... technology for early warning of adverse pregnancy outcomes, ... study by Dr. Thomas McElrath of ... Fetal Medicine,s (SMFM) annual meeting held in ... 2016.  The presentation reported initial positive top-line results ...
(Date:2/10/2016)... 2016  IsoRay, Inc. (NYSE MKT: ISR), a medical ... radioisotope applications for the treatment of prostate, brain, lung, ... financial results for the second quarter and six months ... --> --> Revenue ... 2016, which ended December 31, 2015, a 12% increase ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, ... the promotion of two long-standing principal investigators (PI) to the roles of Chief ... and Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin ...
(Date:2/10/2016)... Charlotte, NC (PRWEB) , ... February 10, 2016 ... ... highly anticipated expansion to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. ... Sonablate® HIFU procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... --Technology Enhancements Accelerate Growth of X-ray Imaging This ... computed radiography markets in Thailand , ... (TIM). It provides an in-depth analysis of ... regional market drivers and restraints. The study offers revenue ... attractiveness, both for digital and computed radiography. Market participants ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
Breaking Biology News(10 mins):